Research Focus

Former Employee. Medicine; Research Stdy Asst II

Recent additions – View all

1. A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer

   Meeting Abstract

   Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Park, J.; Hudis, C.; more...
   Breast Cancer Research and Treatment (2005)

   Fulltext@MSK | Save
2. A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

   Meeting Abstract

   Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Hudis, C.; Rugo, H.
   Journal of Clinical Oncology (2005)

   Fulltext@MSK | Save
3. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC)

   Meeting Abstract

   Dickler, M.; Rugo, H.; Caravelli, J.; Brogi, E.; Sachs, D.; Panageas, K.; Flores, S.; Moasser, M.; Norton, L.; Hudis, C.
   Journal of Clinical Oncology (2004)

   Fulltext@MSK | Save